Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869226 | 1.00 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1UCHL1NR1H2 | |
| SCHEMBL15606327 | 1.00 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1UCHL1NR1H2 | |
| Tert-Butylamine SCHEMBL28919679 | 0.96 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2NPC1UCHL1NR1H2 | |
| Tert-Butylamine SCHEMBL28919678 | 0.96 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2NPC1UCHL1NR1H2 | |
| Tert-Butylamine SCHEMBL934294 | 0.96 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2NPC1UCHL1NR1H2 | |
| SCHEMBL8235326 | 0.88 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2NPC1UCHL1NR1H2 | |
| SCHEMBL10215478 | 0.88 | NPC1 (0.41) | HSD17B10SMN1; SMN2NPC1UCHL1NR1H2 | |
| SCHEMBL17358752 | 0.88 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2NPC1UCHL1NR1H2 | |
| SCHEMBL30289230 | 0.88 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2NPC1UCHL1NR1H2 | |
| SCHEMBL19390003 | 0.88 | NPC1 (0.41) | HSD17B10SMN1; SMN2NPC1UCHL1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220326082-A1 | CHIRAL HETEROSTRUCTURES | Alliance for Energy Innovation, LLC | 2022-10-13 | — | — | US | claimed |
| CN-122036596-A | N- (2 ',6' -xylyl) -2-piperidine carboxamide derivative and application thereof | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2025227148-A1 | BICYCLIC HETEROCYCLE COMPOUNDS FOR TREATMENT OF HERPES VIRUSES | ASSEMBLY BIOSCIENCES, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025227145-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF HERPES VIRUSES | ASSEMBLY BIOSCIENCES, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250223259-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2025-07-10 | — | — | US | disclosed |
| US-20250136620-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. | 2025-05-01 | — | — | US | disclosed |
| US-12289941-B2 | Chiral heterostructures | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2025-04-29 | — | — | US | disclosed |
| CN-116348472-B | Macrocyclic compounds | 旭化成制药株式会社 | 2024-12-03 | — | — | CN | disclosed |
| EP-4460508-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-7199106-B2 | Lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| WO-2007025307-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-07-06 | — | — | US | disclosed |
| WO-2006055070-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1644393-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050215488-A1 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | VICURON PHARMACEUTICALS INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005012320-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | HSD17B10 1234/4885SMN1; SMN2 1169/4885NPC1 208/4885 |
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | LCLAT1, LAS1L, NRDC | HSD17B10 1397/4885SMN1; SMN2 4232/4885NPC1 1694/4885 |
| US-20250223259-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | ACE2, PRSS2, PRSS1 | HSD17B10 933/4885SMN1; SMN2 3903/4885NPC1 432/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | HSD17B10 690/4885SMN1; SMN2 2265/4885NPC1 252/4885 |
| US-20050215488-A1 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PAM, MLYCD, PPT1 | HSD17B10 1865/4885SMN1; SMN2 3752/4885NPC1 1316/4885 |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | LCLAT1, NRDC, LAS1L | HSD17B10 1493/4885SMN1; SMN2 4286/4885NPC1 1634/4885 |
| US-20250136620-A1 | BTK DEGRADER | BTK, CBL, LYN | HSD17B10 3451/4885SMN1; SMN2 3356/4885NPC1 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.